
Keywords: سیکلوفسفامید داخل وریدی; Lupus nephritis; immunosuppression; remission; induction therapy; maintenance therapy; mycophenolate mofetil (MMF); intravenous cyclophosphamide; calcineurin inhibitor; end-stage kidney disease (ESKD); dialysis; renal failure; toxicity; adverse events; me